1. GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

3. Introduction/Background

4. Glycemic Efficacy of Liraglutide in the LEAD Trials

5. Blood Pressure Reduction With Liraglutide: LEADER Results

6. Lipid Characteristics of Patients After 24 Weeks of Treatment

7. Body Weight Reduction With Liraglutide: LEADER Results

8. LEADER Results: Hypoglycemia

9. GLP-1 RAs and Improved Cardiac Function

10. EMPA-REG: Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

11. LEADER: Primary Outcome Results*

12. LEADER: Results for CV Death

13. LEADER Subgroup Analysis: Effect of Liraglutide on Patients With T2DM and Polyvascular Disease

14. LEADER: Time to Composite Endpoint (Macroalbuminuria, Doubling of Serum Creatinine, ESRD, Renal Death)

15. SUSTAIN-6 (Semaglutide): Primary Outcome Results

16. Despite Proven Advantages, Uptake of Newer Glucose-Lowering Agents Remains Low

17. Overcoming Patient Reluctance to Inject

18. Summary and Conclusions

19. Abbreviations

20. Abbreviations (cont)